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Methicillin-resistant  Staphylococcus aureus (MRSA)
continues to be a notable cause of hospital-acquired infec-
tions. A statewide screening and control policy was imple-
mented in Western Australia (WA) after an outbreak of
epidemic MRSA in a Perth hospital in 1982. We report on
statutory notifications from1998 to 2002 and review the 20-
year period from 1983 to 2002. The rate of reporting of
community-associated Western Australia MRSA (WAMR-
SA) escalated from 1998 to 2002 but may have peaked in
2001. Several outbreaks were halted, but they resulted in
an increase in reports as a result of screening. A notable
increase in ciprofloxacin resistance during the study period
was observed as a result of more United Kingdom epidem-
ic MRSA (EMRSA) -15 and -16. WA has seen a persistent-
ly low incidence of multidrug-resistant MRSA because of
the screening and decolonization program. Non–multidrug-
resistant, community-associated WAMRSA strains have
not established in WA hospitals.
R
ecent publications suggest that the epidemiology of
methicillin-resistant Staphylococcus aureus (MRSA)
infections is changing, and hospitalization is no longer
necessarily a risk factor (1–3). Reports indicate that com-
munity-associated MRSA infection is now a worldwide
phenomenon. A common theme in these publications is
that the affected populations are usually marginalized,
indigenous peoples, such as American Indians in the mid-
western United States (4,5), Canadian aboriginals (6,7),
and Pacific Islanders in the southwestern Pacific region
(8,9). Aboriginal Australians also appear to be at higher
risk for community-associated MRSA (10). However,
overcrowding or situations where persons are in close
proximity to others, such as in prisons (11) and on sporting
teams (12), may represent the true risk. The increased
prevalence in children (13) may be due to the enhanced
opportunity for exposure at schools and daycare centers.
In the early 1980s, epidemic MRSA (EMRSA) first
appeared on the east coast of Australia; these strains were
often referred to as eastern Australian MRSA (14).
EMRSA were multidrug resistant, and they became
endemic in many large hospitals throughout Australia,
with the exception of Western Australia (WA) (15). The
establishment of EMRSA in WA hospitals has been pre-
vented because of a screening and control program (see
Methods) and the isolation of the state (14,16,17).
However, late in the 1980s, non–multidrug-resistant com-
munity-associated MRSA emerged in WA (14,18,19).
MRSA isolated from patients living in the remote
Kimberley region in the northern part of the state (Figure
1) were phenotypically and genotypically different from
EMRSA and became known as WAMRSA (18,19). Some
WAMRSA have since acquired a multidrug-resistance
plasmid that encodes resistance determinants, including
trimethoprim, tetracycline, and high-level mupirocin
resistance (14,18,19). During the 1990s, WAMRSAspread
to most regions of WA(14,18), and a substantial number of
cases of infection and colonization occurred in metropoli-
tan Perth by 1997 (20).
This retrospective review of statutory MRSA notifica-
tion data was conducted for the period 1998 to 2002. The
aim of the study was to report changes in reporting rates
over time and by location, to describe the distribution by
age and sex of patients, and to document temporal changes
in antimicrobial resistance patterns. The findings were
compared to those in previous publications that covered
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Background
A statewide screening and control policy was imple-
mented in WAafter an outbreak of EMRSAin a Perth hos-
pital in 1982 (16). The policy involved screening all
patients who were admitted to hospitals from different
states or overseas and all new staff members who had
worked outside WA in the previous 12 months (17). After
screening, patients infected or colonized with MRSA were
isolated and treated; infected or colonized staff members
were prohibited from contact with patients until the organ-
ism was eradicated. In WA, MRSA infection or coloniza-
tion has been a reportable condition since 1985. The WA
Department of Health electronically flags cases of MRSA,
which allows infected persons to be identified and isolated
upon admission to any WA public hospital (17).
Since the screening and control policy was introduced,
the identity of MRSA clinical isolates and those isolated
through screening has been confirmed by a reference lab-
oratory by using standard procedures; antimicrobial drug
susceptibility was determined by Clinical and Laboratory
Standards Institute (formerly NCCLS) methods (21). Until
1997, the reference laboratory was in the Division of
Microbiology and Infectious Diseases at the WACentre for
Pathology and Medical Research; thereafter it was in the
Royal Perth Hospital/Curtin University Gram Positive
Bacteria Typing and Research Unit. 
From 1983 to 1997, MRSAwas categorized as EMRSA
or WAMRSA according to antimicrobial drug resistance
patterns based on previous genetic analysis (14). EMRSA
strains were resistant to β-lactam antimicrobial drugs, gen-
tamicin, or both erythromycin and tetracycline. Strains
resistant to β-lactams only, β-lactams and erythromycin, or
tetracycline but not gentamicin were classified as WAMR-
SA. This approach has several limitations that have been
alluded to in previous publications (14,18,20), such as
changes in susceptibility pattern as a result of plasmid
acquisition. Consequently, a more sophisticated system for
differentiating isolates was developed at the Royal Perth
Hospital laboratory that detected the introduction into WA
of UK EMRSA-15 and Irish-2 strains of MRSA (22).
Data
Information on infection and colonization with MRSA
was obtained from the database held by the Communicable
Diseases Control Branch of the WADepartment of Health.
MRSAcolonization was determined by screening patients,
staff, and contacts by methods as described (17). Isolates
recovered on screening and clinical isolates were sent to
the Royal Perth Hospital laboratory for characterization by
several procedures, including bacteriophage typing, rou-
tine antibiogram, urease production, extended antibi-
ogram/resistogram, coagulase gene typing, and
pulsed-field gel electrophoresis (23,24). Information col-
lected with isolates included basic case demographics and
details pertaining to the organism, including isolation site.
In addition, whether the notification was the result of
MRSA isolates found in a clinical specimen or from a
screening specimen was recorded. Multiple cultures on the
same patient were not included unless it had been deter-
mined that the patient was clear of MRSA colonization or
infection after the process outlined (17).
Crude notification rates for health regions (Figure 1)
were calculated with population estimates based on the
2001 census (25). Differences in proportions were com-
pared by using the chi-square test, while changes over time
were assessed by using chi square for trend.
Results
From 1998 to 2002, a total of 9,955 notifications of
MRSA were made in WA; 1,441 notifications were made
in 1998, 1,767 in 1999, 2,102 in 2000, 2,326 in 2001, and
2,319 in 2002. Table 1 shows the numbers of notifications
and crude notification rates per 100,000 population of the
various health regions of WA. Of the 9,955 notifications,
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Figure 1. Health regions of Western Australia.9,728 gave permanent addresses within WA. The highest
notification rates were recorded in the Kimberley region,
followed by the East Metropolitan and Goldfields regions.
The average yearly notification rate for the whole state
during this period was 107.7/100,000 population. Figure 2
shows notifications of WAMRSAand EMRSAin WAfrom
1983 to 2002. This figure shows a marked increase in
WAMRSAfrom 1991 to 2002 (peak), with a slowing in the
notification rate after 2000. EMRSA peaked in 2001 and
declined in 2002.
The distribution of MRSAby type is shown in Figure 3.
In 1998, 6.4% of MRSA notifications were classified as
EMRSA, increasing to 24.4% in 2002. The greatest con-
tributor to EMRSA was UK EMRSA-15, which rose from
55 reports in 1998 to 383 in 2002. UK EMRSA-16
increased substantially from a few notifications in
2000–2001 to 66 notifications in 2002. Irish-2 notifica-
tions remained constant early in the 5-year period at ≈40
per year but fell to 29 in 2001 and 18 in 2002. Australian
EMRSA was maintained at a variable but relatively low
level, except in 2001 when 131 notifications occurred.
Overall, 94% of community-associated WAMRSA were
classified into 3 clones: ST1-MRSA-IV (55%), ST129-
MRSA-IV (30%), and ST5-MRSA-IV (9%). Of the com-
munity-associated WAMRSA, 97% were staphylococcal
chromosome cassette (SCC) mec type IV and 3% were
SCCmec type V (unpub. data). During this period, Western
Samoan Phage Pattern strains were isolated occasionally.
Some of the variability in notifications was related to
outbreaks and subsequent contact screenings. Overall, 75%
of notifications (7,913) were due to MRSA isolates found
in routine clinical specimens; 25% (1,980) were due to a
survey (Table 2). The annual proportion of isolates due to
screening increased significantly during the 5-year period
(from 10% in 1998 to 39% in 2002) (chi square for trend
35.696, p<0.0001). Of the 1,980 MRSAdetected in screen-
ing specimens, 86.7% were WAMRSA. Of the 9,889 noti-
fications over the 5-year period where the appropriate
information was provided, 93% were due to MRSAisolates
found in patient specimens, however, 5% of notifications
involved staff, and 2% were from other contacts (Table 3).
The number of notifications due to a staff member who had
MRSA increased from 73 in 2000 to 173 in 2001.
The distribution of MRSA cases from 1998 to 2002 by
age and sex is shown in Figure 4. Notification rates peaked
in age groups <9 years of age, 20–39 years of age, and
70–89 years of age. Overall, there was a 1:1.1 female-to-
male ratio in notifications. In the 20- to 39-year age group,
a predominance of female cases was reported; in the 60- to
79-year age group, male notifications predominated. In the
>80-year age group, a 61.7% predominance of female
notifications was seen; however, this figure was only
slightly different than the 64.7% proportion of women in
the WA population >80 years of age.
Data were collected on the susceptibility of MRSAiso-
lates to various antimicrobial agents (Table 4). All isolates
were susceptible to vancomycin, cotrimoxazole, and clin-
damycin. Most of the isolates were susceptible to
mupirocin. Susceptibility to trimethoprim, tetracycline,
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Figure 2. Notifications of methicillin-resistant Staphylococcus
aureus (MRSA) in Western Australia (WA), 1983–2002, WAMRSA
versus epidemic MRSA. Note: Not included are 4 in 2001 and 12
in 2002 of Western Samoan Phage Pattern.and fusidic acid varied, although these antimicrobial drugs
remained reasonably active throughout the data collection
period. Approximately 40% of MRSA isolates remained
susceptible to erythromycin. The only notable change was
a significant increase in the resistance of ciprofloxacin,
from 11% in 1998 to 26% in 2002 (chi square for linear
trend 8.940, p = 0.002), consistent with the increase in
numbers of UK EMRSA-15, UK EMRSA-16, and Irish-2
strains. The proportion of multidrug-resistant strains var-
ied from 5.6% in 1998 to 10.4% in 2001. 
Discussion
The increasing prevalence of community-associated
MRSA is a global public health concern. In WA, coloniza-
tion or infection with MRSA has been a reportable condi-
tion for >20 years, either voluntarily from1983 to 1984 or
by law since 1985. This time span has afforded a unique
opportunity to document 2 important occurrences, 1) pre-
venting EMRSA from becoming established in the hospi-
tal system and 2) emerging community-associated MRSA
throughout WA.
The epidemiology of MRSAin WAhas always differed
from that in the rest of Australia because of the “search and
destroy” policy (16,26,27) adopted in the early 1980s. In
that decade, the proportion of S. aureus that was MRSA
varied from 10% to 30% in states other than WA, while
WA remained at 0.4% (17). After a relatively low number
of MRSA notifications in the 1980s in WA, the number
increased dramatically in the 1990s. This increase was due
almost exclusively to community-associated WAMRSA.
The proportion of WAMRSA notifications after 1989 rose
remarkably, increasing from 14% to 94% of total notifica-
tions in 1998. An almost exponential trend of MRSA noti-
fications was evident, although a possible reporting bias
may have occurred as a result of sporadic outbreaks at var-
ious times. As is evident from Figure 2, the epidemic of
WAMRSAmay have peaked; however, several more years
of data are required to verify this. Although MRSA now
causes 10% of S. aureus bacteremia in WA (28), the pro-
portion is much lower than that seen in other Australian
states (29). After 1998, the number of EMRSA notifica-
tions in WAstarted to increase after the introduction of UK
EMRSA-15, in particular, and the Irish-2 strains (22).
Significant changes in proportions of WAMRSA iso-
lates that occurred in the Perth metropolitan area were not
noticeable until 1991, which suggests spread from the
remote Kimberley region in the northern part to the south-
ern half of the state. The Kimberley region has a total pop-
ulation of ≈30,000 in a 25,000-km2 area. Approximately
half the population is indigenous peoples, many of whom
live in poor socioeconomic conditions. Infected skin
lesions and staphylococcal sepsis occur frequently in this
population, and empiric antistaphylococcal therapy is often
prescribed (17). Some of the disease spread to the south
may be attributed to transporting patients from this region
to tertiary hospitals in Perth, particularly Royal Perth
Hospital, a major trauma center in the eastern metropolitan
area. In addition, a large population of “fly-in/fly-out”
workers are employed in the area (14). Finally, traditional-
ly indigenous populations in Australia are highly mobile.
The highest notification rates of MRSAcontinued to be
in the Kimberley region throughout the study period,
which suggested continued involvement of the aboriginal
population. However, from 1998 to 2002, the second high-
est notification rate in the state was the East Metropolitan
region of Perth. Historically, Royal Perth Hospital has had
more MRSA outbreaks than other Perth hospitals (14,18),
primarily because of the case-mix at Royal Perth Hospital;
consequently, Royal Perth Hospital conducts more screen-
ing than other hospitals. Until 1997, WAMRSA had not
caused outbreaks when patients who were infected were
admitted to hospitals, however, during that year an out-
break of a fusidic acid–resistant WAMRSA occurred at
Royal Perth Hospital after a patient from another remote
rural location (30) was admitted. From 1983 to 2002, noti-
fication rates increased >50- and 70-fold in rural and met-
ropolitan health regions, respectively.
In 1983, the overall rate of notifications in the rural
regions was 10/100,000 compared with the metropolitan
area rate of 7/100,000 (14). In 2002, notification rates in
rural and metropolitan regions were 108 and 104 notifica-
tions per 100,000 persons, respectively. In rural regions,
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Figure 3. Methicillin-resistant Staphylococcus aureus (MRSA) in
Western Australia, 1998–2002, by type.the greatest increase in notification rates since 1983
occurred in the Pilbara, Mid West & Gascoyne, and Great
Southern health regions with 56-, 48-, and 45-fold increas-
es, respectively. In the metropolitan regions, the South,
East, and North Metropolitan notification rates for 2002
were 50-, 23-, and 8-fold higher, respectively, than those
reported in 1983.
From 1998 to 2002, 3 peaks in the age and sex distribu-
tion of notification rates were apparent: increases in the
<9-, 20- to 39-, and 60- to 89-year age groups; male pre-
dominance in the 60- to 79-year age group; and female
predominance in the 20- to 39-year age group. This female
predominance was because the screenees were either nurs-
es on staff or persons who were being screened for poten-
tial employment.
Since 1998, notifications as a result of screening
increased 4-fold. If the screening tests were removed from
the totals, male cases predominated in all age groups. This
pattern of age and sex distribution has changed minimally
since 1983 (14,20). 
From 1998 to 2002, the proportion of MRSA notifica-
tions due to screening increased from 10% to 39%.
Screening is still a controversial issue. A recent review
concluded that screening of at least high-risk patients was
necessary to reduce rates of MRSAinfections in hospitals;
however, further validation, from a variety of different
institutions, of the cost-effectiveness of such programs was
suggested and would be valuable (31). In WA in 1982, a
unified approach to controlling multidrug-resistant MRSA
was implemented. The approach was to screen all patients
on admission who had been hospitalized or staff members
who had worked in a hospital outside WA within the pre-
vious 12 months (17). Individual hospitals have varied in
their approach to controlling non–multidrug-resistant
MRSA, which is now endemic in the WA community, but
not WA hospitals.
From 1983 to 1992, the agents for which a major
change in susceptibility was observed were tetracycline
(an increase from <10% to ≈30%), erythromycin (≈10% to
≈40%), and clindamycin (≈30% to ≈80%) (14). These
changes reflected the increasing proportions of non–
multidrug-resistant WAMRSA notifications. In 1993, 68%
and 65% of WAMRSAwere susceptible to tetracycline and
erythromycin, respectively (8). The only significant
changes from 1994 to 1997 were that fusidic acid resist-
ance increased from 4.6% to 12.4% (20), and mupirocin
resistance decreased from 6.4% to 0.3% after an earlier
high of 18% in 1993 (32). Udo et al. first reported high-
level mupirocin resistance in WAMRSA strains. This
resistance was encoded on a transferable plasmid, which
also carried resistance determinants for tetracycline,
trimethoprim, and cadmium toxicity (33). Mupirocin was
used frequently in the northern part of the state to treat
infected skin lesions, which resulted in the emergence,
selection, and amplification of a mupirocin-resistant strain
of WAMRSA. As a result, guidelines restricting the use of
mupirocin were implemented; it was not to be used with-
out laboratory control, its use should not exceed 10 days,
and >1 month should elapse before further use for the same
patient (32). After these measures were implemented,
mupirocin resistance fell to levels <1% (32). This low
level of resistance has been maintained for the last 5 years. 
Resistance to fusidic acid in WAMRSA continues to be
a concern. Resistance has gradually risen from 3% of
MRSA notifications in 1993 to 5% in 1994, 9% in 1995,
and 12% in 1997 (34). From 1998 to 2001, resistance to
fusidic acid ranged from 11% to 13% of MRSA, with a
slight fall to 8% in 2002. The emergence of fusidic acid
resistance in WAMRSAparalleled the decline in mupirocin
resistance; some practitioners may have replaced 1 topical
antimicrobial drug with another after the guidelines were
implemented. The emergence of ciprofloxacin resistance is
also of concern. In 1998, 11% of all MRSA isolates were
resistant to ciprofloxacin, increasing to 26% in 2002. This
change reflects the introduction of UK EMRSA-15, UK
EMRSA-16, and Irish-2 into the state (22). Ciprofloxacin
has been suggested as a possible agent for MRSA decolo-
nization (35) and has, at times, been recommended for this
purpose by the WADepartment of Health. This recommen-
dation may need to be reviewed.
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Figure 4. Notifications of methicillin-resistant Staphylococcus
aureus in Western Australia, 1998–2002, by sex and age group.Endemic persistence of MRSA and the measures that
should be undertaken to control or eradicate it from hospi-
tals are likely to remain topical subjects. WA has success-
fully halted multidrug-resistant MRSA outbreaks. The
state has seen a persistently low incidence of multidrug-
resistant MRSA because a vigilant screening and decolo-
nization program was implemented. During the last 5
years, growth of non–multidrug-resistant, community-
associated WAMRSA has been exponential, and rural and
metropolitan rates have apparently stabilized. However,
new epidemic strains of MRSA, such as UK EMRSA-15,
which were seen initially in 1999, steadily increased in
2000 and 2001. The infection control precautions institut-
ed for patients infected with these strains were the same as
those with multidrug-resistant MRSA. We do not know
whether this approach will work or whether a similar dra-
matic rise in prevalence of these strains, as seen in UK hos-
pitals recently, will occur (36).
Ms Dailey is a PhD student who is working on surveillance
systems for healthcare-related infections. The work reported in
this article was the basis of her MPH dissertation in 2003.
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